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PS3, A Semisynthetic b-1,3-Glucan Sulfate,
Diminishes Contact Hypersensitivity Responses
Through Inhibition of L- and P-Selectin Functions
Susanne Alban1,8, Ralf J. Ludwig2,3,8, Gerd Bendas4, Michael P. Scho¨n5,6, Gertie J. Oostingh5,7,
Heinfried H. Radeke3, Juliane Fritzsche4, Josef Pfeilschifter3, Roland Kaufmann2 and Wolf-Henning Boehncke2
Leukocyte extravasation is initiated by an interaction of selectin adhesion molecules and appropriate
carbohydrate ligands. Targeting those interactions seems a promising approach to treat chronic inflammation.
We developed a b-1, 3-glucan sulfate (PS3) with inhibitory activity toward L and P-selectins under static
conditions. Here, detailed investigation showed inhibition of P- and L-selectins, but not E-selectin under flow
conditions (relative reduction of interaction with appropriate ligands to 34.4±16.6, 8.5±3.6, or 99.5±9.9%,
respectively, by PS3 for P-, L- or E-selectin). Intravital microscopy revealed reduction of leukocyte rolling in skin
microvasculature from 22.7±5.0 to 12.6±4.0% after injection of PS3. In the next experiments, mice were
sensitized with 2,4,-dinitrofluorobenzene (DNFB), and lymphocytes were transferred into syngeneic recipients,
which were challenged by DNFB. Inflammatory responses were reduced when immunity was generated in mice
treated with PS3 or in L-selectin-deficient mice. No effect was observed when L-selectin-deficient donor mice
were treated with PS3, further suggesting that PS3 acted primarily through inhibition of L-selectin. Elicitation of a
contact hypersensitivity response was reduced in P-selectin-deficient and in PS3-treated mice. Again, PS3 had
no effect in P-selectin-deficient mice. PS3 is a potent P- and L-selectin inhibitor that may add to the therapy of
inflammatory diseases.
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INTRODUCTION
Constant migration of leukocytes through blood, lymphoid
system, and organs is a basic prerequisite for immune
surveillance and host defense. However, uncontrolled and/
or misdirected leukocyte migration leads to immune-
mediated diseases, such as inflammatory bowel diseases,
multiple sclerosis, psoriasis, or rheumatoid arthritis (O’Dell,
2004; Scho¨n and Boehncke, 2005). To move from the
bloodstream into tissues, leukocytes must interact with the
endothelial lining of the vasculature. This process of
leukocyte extravasation (Butcher and Picker, 1996; Scho¨n
and Ludwig, 2005) is initiated by an interaction of selectin
adhesion molecules with their appropriate ligands (Weninger
et al., 2000). Hence, selectin–ligand interactions are promis-
ing therapeutic targets in chronic inflammatory diseases
(Zarbock et al., 2007; Ludwig et al., 2007b). In support of this
hypothesis, clinical trials with pan-selectin-inhibitory com-
pounds, for example TBC1269 (Friedrich et al., 2006) or
recombinant P-selectin glycoprotein ligand-1 (rPSGL-Ig;
Mertens et al., 2006), often showed a beneficial effect in
inflammatory processes. However, specific inhibition of E-
selectin alone by infusion of a function-blocking monoclonal
antibody had no effect in patients suffering from psoriasis
(Bhushan et al., 2002).
Whereas TBC1269 and rPSGL-Ig inhibit all three selectins
(Hicks et al., 2003; Kranich et al., 2007), heparins possess
only P- and L-selectin-inhibitory activities (Borsig, 2004).
Although heparins exert a wide range of biological activities
(Lever and Page, 2002; Ludwig et al., 2006b; Buller et al.,
2007), their P- and L-selectin-inhibitory activity is thought to
be especially important for both their anti-inflammatory and
antimetastatic activities (Ludwig et al., 2006b; Buller et al.,
2007), may be also involved in their antithrombotic activity
(Polgar et al., 2005), and thus contribute to their overall
therapeutic efficacy. A broad use of heparins as anti-
inflammatory drugs may, however, be hindered by several
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reasons (Alban, 2005a, b). Most importantly, heparins exhibit
strong antithrombin-mediated anticoagulant activities, the
risk of bleeding limits their therapeutic use in inflammation or
cancer treatment. As natural products consisting of variable
complex mixtures of glycosaminoglycans, heparins show
certain batch-to-batch variation, resulting in inconsistencies
with regard to selectin inhibition (Alban, 2005a; Fritzsche
et al., 2006). Among different heparin preparations, pro-
nounced differences in their extent of selectin inhibition and
thus pharmacological activity in vivo were found (Stevenson
et al., 2005; Ludwig et al., 2006a; Simonis et al., 2007).
Recently, heparin-related safety issues have come into the
focus of the medical community (FDA, 2008). Structural
modifications, for example, reduction of uronic acid
residues, have led to P-selectin-binding heparin derivatives
without antithrombin-mediated anticoagulant activity (Xie
et al., 2000; Gao et al., 2005). The other disadvantages of
heparins, such as their non-human origin, shortage on
resources, and their batch-to-batch variability, were not
eliminated by this approach and limit the broad use as anti-
inflammatory drugs.
We pursued the strategy of developing structurally defined
glucan sulfates obtained by chemical modifications of neutral
homoglucans produced by algae, bacteria, or fungi. The aim
was to produce compounds with reduced anticoagulant
activity, but stronger anti-inflammatory and/or antimetastatic
activity compared to heparin (Becker et al., 2003a). Studies
on structure–activity relationships and optimization of the
semisynthetic procedure led to the highly sulfated b-1,3-
glucan sulfate (PS3; Yvin et al., 2002; Becker et al., 2003b). In
assays under static conditions, these semisynthetic glucan
sulfates structure and concentration dependently inhibited
cell adhesion to P- and L-selectins, but not to E-selectin (Yvin
et al., 2002). Under flow conditions, they showed similar
structure–activity relationships and considerably stronger P-
selectin-inhibitory activity than heparin (Hopfner et al., 2003;
Fritzsche et al., 2006). These findings suggested that P- and/or
L-selectin may represent worthwhile targets for this type of
sulfated polysaccharides. The aim of this study was to
investigate the inhibitory activity of the PS3, which was
selected because of its potent in vitro P- and L-selectin-
inhibitory activity (Fritzsche et al., 2006), on cell–cell and
cell–selectin interactions and its impact on P- and L-selectin-
mediated functions in animal models of cutaneous inflam-
mation.
RESULTS
Synthesis and characterization of PS3
PS3 is a well-defined, reproducible semisynthetic b-1,3-
glucan sulfate (existing as sodium salt), which is obtained by
chemical modification of the uncharged, small b-1,3-glucan
Phycarine (Figure 1; Yvin et al., 2002; Me´nard et al., 2004).
Phycarine is isolated from the brown algae Laminaria digitata
and consists of a b-1,3-glucan backbone with an average
degree of polymerization of 25 and one or two C6
ramifications with glucose. The chemical sulfation of
Phycarine was performed with SO3–pyridine complex ac-
cording to the method described by Alban et al. (1992),
which had been optimized to obtain regular b-1,3-glucan
sulfation without any polysaccharide degradation and to
control the resulting degree of sulfation. Structure analysis
revealed that the primary OH group in position 6 of PS3 is
fully sulfated, whereas the two secondary OH groups in
positions 2 and 4 are equally sulfated to about 60% under the
used conditions (Yvin et al., 2002; Me´nard et al., 2004). The
overall degree of sulfation of PS3 is 2.2 sulfate groups per
glucose unit. PS3 has a molecular mass Mr of about 10,000,
and like the starting polymer a low polydispersity. Similar to
heparins and in contrast to Phycarine, PS3 exhibits a wide
range of biological activities by interfering with processes
involving endogenous glycosaminoglycans. However, it
shows mostly stronger pharmacological effects than heparins
in assays indicating potential anti-inflammatory and anti-
metastatic activities (for example, PS3 is significantly superior
to heparins in in vitro P- and L-selectin adhesion assays),
whereas its anticoagulant activity is considerably weaker (for
example, the concentration for doubling the activated partial
thromboplastin time is seven times higher than that of
unfractionated heparin) (Yvin et al., 2002; Alban et al.,
2005). PS3 passed the basic toxicity tests as prerequisite for
clinical studies in humans. In addition, intravenous applica-
tion of PS3 in monkeys revealed that it is well tolerated and
results in stronger release of tissue factor pathway inhibitor
than heparin (Alban et al., 1997).
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Figure 1. Structure of PS3. PS3 is the sodium salt of a b-1,3-glucan sulfate with a degree of sulfation (DS) of 2.2, a degree of polymerization (DP) of about 25
corresponding to a mean molecular mass (Mr) of 10,000.
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Inhibition of PBMC–endothelial cell interactions by PS3 under
flow conditions
To investigate whether PS3 inhibited selectin-dependent
leukocyte–endothelial cell interactions on the cellular level, a
dynamic flow chamber system with a matrix of human
umbilical vein endothelial cells and suspended peripheral
blood mononuclear cells (PBMCs) was used. PS3 significantly
inhibited the binding interactions between PBMC and tumor
necrosis factor-a (TNF-a)-activated human umbilical vein
endothelial cells at concentrations as low as 5mgml1
(P¼0.02 as compared to control conditions; Figure 2). This
inhibition dose dependently increased up to 75% at a
concentration of 50mgml1 PS3 (Po0.001 compared to control
conditions). Higher PS3 concentrations up to 1,000mgml1 did
not further improve the inhibitory effect. A cocktail of antibodies
directed against E-, P- and L-selectins had a similar inhibiting
effect (80% inhibition, Po0.001 compared to control condi-
tions). On the basis of leukocyte and endothelial expression
patterns of adhesion molecules, and the effects on selectins
under static conditions (Yvin et al., 2002; Becker et al., 2003b),
the effect by PS3 is most likely to be mediated by an interaction
of leukocyte PSGL-1 with endothelial P-selectin. To further
investigate which pathways are impaired by PS3, we performed
experiments with defined selectin ligands.
PS3 impairs P- and L-, but not E-selectin-mediated interactions
under flow conditions
To gain further insight into the molecular basis of PS3’s ability
to inhibit binding interactions between PBMC and activated
endothelial cells, we used defined conditions that allowed to
investigate the effects of PS3 on each selectin separately.
First, the inhibitory effect of PS3 on interactions of the
PSGL-1 expressing human monocytic cell line U937 with
immobilized P-selectin was investigated under conditions of
shear flow. Presence of PS3 in the flow chamber led to a
significant reduction of U937 interactions with immobilized
P-selectin by 65% (P¼ 0.016; Figure 3). To further validate a
specific P-selectin inhibition by PS3 we tested for dose–
response relationship. Whereas PS3 at a concentration of
5 mgml1 had no effect on U937 and P-selectin interaction,
doses of 50, 100, and 500mgml1 had a profound effect.
Maximal inhibition was observed with 100 mgml1, and an
increase of PS3 concentration did not lead to a further
reduction (Figure 3b). The inhibitory effect of PS3 on the
interaction between human PBMC and immobilized sialyl
Lewis X (sLex)/TS-PAA, a synthetic ligand for all three
selectins with a strong affinity for E-, and L-selectins, was
tested under conditions of shear flow. As L-selectin is the only
selectin expressed on PBMC, it is reasonable to assume that
any inhibitory effects in this system were because of the
interference with L-selectin functions. Similar to the U937/P-
selectin assay, PS3 turned out to be a potent inhibitor of the
interactions between PBMC and sLex/TS-PAA at concentra-
tions as low as 5 mgml1 (Po0.001). This inhibitory effect
was dose dependent, and at concentrations 4500mgml1,
almost complete inhibition (that is, 490%) could be
observed (Figure 3). L-selectin-specific antibodies at a final
concentration of 10 mgml1 also significantly inhibited this
interaction (Po0.001), albeit to a somewhat lesser extent as
compared to higher concentrations of PS3 (not shown). The
effect of PS3 on the interaction of E-selectin expressing CHO
(E-CHO) cells with the E-selectin ligand sLexLac1 was
evaluated. In contrast to the effects observed with P and L-
selectins, adherence of E-CHO cells under shear remained
unchanged in the presence of PS3 (Figure 3). This is in
accordance with previous results under static conditions,
where PS3 concentration dependently reduced the cell
adhesion to immobilized P- and L-selectins, but not to E-
selectin (Yvin et al., 2002).
PS3 impairs P-selectin function in vivo
In the next series of experiments, we assessed whether the
in vitro observed effects of PS3 on P- and L-selectin function
were also relevant in vivo. For this purpose, superantigen-
activated PBMCs were fluorescently labeled and injected into
C57Bl/6 mice or P-selectin-deficient mice. Rolling inter-
actions of fluorescent cells within the same vessels before and
after PS3 treatment were then observed by intravital micro-
scopy in the skin microvasculature. As expected (Weninger
et al., 2000), rolling interactions of leukocytes were reduced
in P-selectin-deficient mice (rolling fraction: 3.6%±1.8%) as
compared to wild-type C57Bl/6 mice (rolling fraction: 22.7%
±5.0%; P¼0.006). In wild-type mice, a single injection of
25mg kg1 PS3 reduced the rolling interactions to
12.6±4.0% (decrease by 45%; P¼ 0.014, paired t-test). In
contrast, no further effect of PS3 was seen in P-selectin-
deficient mice, suggesting that the observed reduction in
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Figure 2. PS3 inhibits interactions between PBMCs and endothelial cells
under conditions of shear flow. TNFa-activated endothelial cells, coated on
plastic coverslips, were mounted in a flow chamber system and human
PBMCs were allowed to interact with these endothelial cells under conditions
of shear flow (1.12ml per hour). Cell–cell interactions were recorded in real
time after 20minutes. The average of six independent pictures was used to
analyze the number of PBMC binding to the endothelial cells and the data are
presented as the relative number of adhering cells, whereby this number was
set to 100% in the absence of PS3 for each PBMC donor (n¼ 3) ±SEM.
Concentrations as low as 5 mgml1 PS3 could significantly inhibit the
adherence of PBMC to the stimulated HUVECs (*Po0.05, **Po0.01,
***Po0.001, one-way ANOVA with Bonferroni t-test for pair-wise multiple
comparisons). An antibody cocktail, containing antibodies blocking all three
selectins significantly inhibited the binding interactions by 80%. However,
complete inhibition by either PS3 or anti-selectin-Ab cocktail was not
observed. This residual binding is most likely due to an interaction of
leukocyte integrins (e.g., VLA-4) with appropriate ligands on the HUVEC (e.g.,
VCAM-1), which have been shown to mediate rolling in the skin
microvasculature (Butcher and Picker, 1996).
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rolling interactions was primarily due to inhibition of P-
selectin (Figure 4).
Adoptive transfer of immunity toward a contact allergen is
reduced after treatment with PS3
To evaluate if above in vitro and in vivo findings were
relevant in an inflammatory disease model, we sought to
investigate the effects of PS3 in a murine cutaneous
hypersensitivity response model. Given that L-selectin func-
tions are relevant to generate immunity by facilitating homing
of naive T lymphocytes to peripheral lymph nodes (Catalina
et al., 1996; Oostingh et al., 2007a), we expected that PS3
treatment during the sensitization against a topically applied
contact allergen would impair generation of immunity. For
this purpose, wild-type or L-selectin-deficient mice were
sensitized with 2,4,-dinitrofluorobenzene (DNFB) and simul-
taneously treated with PS3. Once immunity was established
(5 days after sensitization), isolated lymph node and spleen
cells from these mice were adoptively transferred into
syngeneic wild-type recipient mice, which were then
exposed to DNFB. As reported earlier (Catalina et al.,
1996), L-selectin deficiency led to a decreased immune
response in adoptive transfer experiments (D ear swelling
35.6±4.0 cm 103 in wild-type animals compared to
21.0±1.5 cm 103 in mice lacking L-selectin expression).
Likewise, PS3 treatment of wild-type donor mice leads to a
diminished immune response in recipient mice (D ear
swelling 13.2±3.1 cm103). Injection of PS3 in L-selec-
tin-deficient mice had no additional effects in recipient wild-
type animals (D ear swelling 12.3±3.1 cm103; Figure 5).
Therefore, the immunosuppressive effect of PS3 can, at least
in part, be attributed to inhibition of L-selectin during the
sensitization phase.
Contact hypersensitivity reactions respond to treatment
with PS3
In addition to hindrance of the generation of immunity by
PS3, the compound could also affect the P-selectin-depen-
dent extravasation of leukocytes to the skin (Subramaniam
et al., 1995) following exposure to DNFB (elicitation phase).
To test this hypothesis, wild-type or P-selectin-deficient mice
were sensitized with DNFB. Concomitantly with the second
exposure to DNFB, both groups of mice were injected with
PS3 or solvent alone. In this model of DNFB-induced contact
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Figure 3. PS3 inhibits P- and L-, but not E-selectin function under conditions of shear flow. Flow chamber experiments to assess the influence of PS3 on
P-, L-, or E-selectin function were performed as described in Materials and Methods. (a) Although a profound inhibition P- and L-selectin functions is observed
after PS3 treatment, E-selectin functions remain unaffected (data showed are from experiments using 100 mgml1 for all selectins). (b) Inhibition of U937
cells with P-selectin-coated surfaces by PS3 was dose depended. A significant inhibition was observed at a concentration of 50 mgml1, but not at lower
concentrations. Maximum inhibition was detected at a dose of 100mgml1, and an increase to 500 mgml1 did not yield additional effects. (c) Likewise, the
effect of PS3 on L-selectin function also proved to be dose dependent. Compared to the inhibition of P-selectin function, the effect on L-selectin was even
more pronounced, with no detectable interactions at PS3 concentrations of 500 mgml1 or more. Data have been obtained from at least four independently
performed experiments for each selectin. Statistical evaluation performed with either paired t-test or signed-rank test, as appropriate (*Po0.05).
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hypersensitivity response, P-selectin-deficient mice showed
significantly diminished ear swelling (1.1±1.5 cm103) as
compared to wild-type mice (15.1±1.3 cm 103;
P¼0.014; Figure 6). In addition, a significant decrease of
the inflammatory response was observed when wild-type
mice were treated systemically with PS3 (D ear swelling
1.5±0.7 cm103; Po0.001 compared to vehicle-treated
mice; Figure 5). In mice lacking P-selectin expression, PS3
has no further inhibitory effect (Figure 5). Thus, the apparent
therapeutic effect of PS3 treatment was presumably due to
inhibition of P-selectin function in the wild-type mice.
DISCUSSION
Comparing several glucan sulfates (phycarin, curdlan, or
pullulan sulfates) for their P-selectin-inhibitory capacity
in vivo to identify structural parameters attributable to
P-selectin inhibition, we identified a phycarin sulfate with a
profound inhibitory activity comparable to a function-
blocking P-selectin-directed antibody (Fritzsche et al.,
2006). Using this highly active P-selectin-inhibitory glucan
sulfate (termed PS3), we have shown an additional L-selectin
but not E-selectin-inhibitory activity of PS3 under in vitro flow
conditions. In addition, we could show inhibition of
lymphocyte rolling by PS3 in vivo. As both P- and L-selectins
contribute to the pathogenesis of chronic inflammatory
disease (Uchimura and Rosen, 2006; Ludwig et al., 2007b),
we evaluated the use of PS3 as an anti-inflammatory agent in
a murine model of contact hypersensitivity. Our results show
a clear reduction of the inflammatory response by PS3 in two
complementary models, the adoptive transfer of immunity
(sensitization phase), and the challenge with contact allergen
(elicitation phase). We confirmed in the adoptive transfer
model that L-selectin deficiency of donor mice diminishes the
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Figure 4. PS3 impairs P-selectin function in vivo. Superantigen-stimulated
PBMCs were injected into C57Bl/6 (þ /þ ) or P-selectin-deficient (P-sel/)
mice. Rolling interactions of cells in the skin microvasculature before and
after i.v. treatment with 25mg kg1 bodyweight PS3 were observed using
intravital microscopy. As expected, rolling interactions are impaired in
P-selectin-deficient mice (Weninger et al., 2000). In addition, PS3 reduces
rolling interactions in the skin microvasculature through inhibition of
P-selectin. Data are presented as mean ± standard error. Results are from
nine vessels from three C57Bl/6 and seven vessels of two P-selectin-deficient
mice. Comparisons within one group were performed using the paired t-test,
whereas the t-test was used for comparison of rolling in C57Bl/6 and
P-selectin-deficient mice.
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Figure 5. PS3 treatment hinders generation of immunity through inhibition
of L-selectin. C57Bl/6 (þ /þ ) or L-selectin-deficient (L-sel/) mice were
sensitized using DNFB. Before topical application of the chemical, mice were
either i.v. treated with 25mg kg1 PS3 or solvent alone. Donor mice were
killed and leukocytes were isolated from peripheral lymph nodes and spleen,
which were transferred into recipient C57Bl/6 mice. Recipients were
simultaneously challenged with DNFB. After 24 hours, ear swelling response
was evaluated. In accordance with previous reports (Catalina et al., 1996), we
confirm a major, but not sole, role of L-selectin for generation of immunity in
peripheral lymph nodes. We furthermore provide evidence that PS3 hinders
generation of immunity through inhibition of L-selectin. Data are presented as
mean±standard error. Results are from 11 to 18 mice per experimental
condition. One-way ANOVA was used for statistical comparisons; pair-wise
multiple comparisons were performed using the Bonferroni t-test.
Mice Treatment Δ Ear swelling (cm × 10–3) P
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Figure 6. PS3 treatment diminishes the effector phase of a contact
hypersensitivity response. C57Bl/6 (þ /þ ) or P-selectin-deficient (P-sel/)
mice were sensitized and challenged with DNFB. Before challenge with the
chemical, mice were either treated with 25mg kg1 PS3 or solvent alone.
After 24 hours, ear swelling response was evaluated. Here we show that
treatment of wild-type mice with PS3 leads to a profound inhibition of the
contact hypersensitivity response. As no effect of PS3 is observed in P-
selectin-deficient mice, this effect of PS3 seems predominantly mediated
through an inhibition of P-selectin. Data are presented as mean±standard
error. Results are from 6 to 18 mice per experimental condition. One-way
ANOVA was used for statistical comparisons; pair-wise multiple comparisons
were performed using the Bonferroni t-test.
1196 Journal of Investigative Dermatology (2009), Volume 129
S Alban et al.
Glucan Sulfates as L- and P-Selectin Inhibitors
inflammatory response in wild-type donor mice (Catalina
et al., 1996; Diacovo et al., 1998). In these donor mice, PS3
treatment had no additional effect on ear swelling of the
recipients. Thus, the immunosuppressive effects of PS3 are
most likely mediated, at least in part, through L-selectin
inhibition in the phase of sensitization in the lymph nodes.
PS3 treatment of P-selectin-deficient mice during challenge
with DNFB had no effect, indicating that PS3’s anti-
inflammatory activity is mainly because of inhibition of P-
selectin function.
As shown here and elsewhere (Arbones et al., 1994;
Catalina et al., 1996; Maly et al., 1996; Collins et al., 2001),
interactions of L-selectin with appropriate ligands, for
example, peripheral lymph node adressin, significantly
contribute to the generation of immunity. Interactions of
L-selectin with its ligands allow rolling of naive T lympho-
cytes along class I–III vessels in peripheral lymph nodes (von
Andrian, 1996), which initiates extravasation (Butcher and
Picker, 1996) to and antigen presentation in the lymph node.
In addition to L-selectin, P-selectin may contribute to the
generation of immunity (at least in L-selectin-deficient mice),
as infusion of P-selectin-expressing, activated human plate-
lets into L-selectin-deficient mice during sensitization with
DNFB led to reconstitution of immunity in those mice, by
forming platelet–leukocyte aggregates, which allow leukocyte
rolling in lymph nodes (Diacovo et al., 1998). This contribu-
tion of P-selectin to the generation of immunity might explain
why treatment of wild-type donor mice with PS3 led to a
more pronounced reduction of the CHS response as
compared to L-selectin donor mice. Extravasation of leuko-
cytes into sites of inflammation also relies on the expression
of L- and P-selectins: several sites of inflammation express L-
selectin ligands (Michie et al., 1993; Arvilommi et al., 1996),
which may allow L-selectin-dependent leukocyte extravasa-
tion to those inflamed tissue sites (Arbones et al., 1994;
Tedder et al., 1995; Collins et al., 2001). Deficient P-selectin
expression in mice (Mayadas et al., 1993) directly and
indirectly leads to reduced inflammatory responses in several
model systems and can presumably be attributed to the lack
of both platelet and endothelial P-selectin (Subramaniam
et al., 1995; Robinson et al., 1999; Schober et al., 2002; Huo
et al., 2003; Manka et al., 2004). This profound contribution
of L- and P-selectins to the pathogenesis of several
inflammatory conditions may explain the significant effects
observed by PS3 treatment in both of our models of
cutaneous inflammation.
Although PS3 turned out to antagonize L- and P-selectins,
it did not influence E-selectin. Also, heparin fractions
and heparin sulfate were found to be inactive against
E-selectin (Skinner et al., 1991; Albelda et al., 1994). All
three selectins bind to sLex, but in contrast to the natural
P/L-selectin ligands, the E-selectin ligands contain no
negatively charged substituents (McEver, 2001). The E-
selectin binding to its ligand seems to occur independently
of ionic interactions. Therefore, polyanions such as PS3 may
be unable to displace the ligands from E-selectin. As P- and
L-selectins were found to be more important for the initial
leukocyte rolling than E-selectin (Labow et al., 1994),
inhibition of P/L-selectin might be sufficient to efficiently
inhibit extravasation.
Current treatment strategies for patients with chronic
inflammatory diseases are mainly based on immunosuppres-
sion (Weinblatt et al., 1999; Scho¨n and Boehncke, 2005).
Despite its pronounced anti-inflammatory activities, PS3
differs in several aspects from classical immunosuppressant
drug substances. First, the binding of glycans to their targets is
typically reversible and not as tight as those of antibodies to
their antigens or tailored xenobiotic chemical entities to their
target molecules (Mulloy, 2005). These distinct binding
characteristics become obvious regarding the selectin–glycan
interactions mediating the rolling of leukocytes and the
interactions between proteins responsible for firm cell
adhesion. Second, PS3 is structurally comparable with
endogenous glycosaminoglycans. Among them, especially
the heparan sulfates are known to exhibit important (patho-)
physiological functions by mediating cell–cell and cell–
extracelullar matrix interactions and binding to a large
number of biomolecules such as enzymes, enzyme inhibitors,
growth factors, chemokines, or cell receptors (Lindahl et al.,
1998). Heparan sulfates and also other glycans are thus
strongly involved in the (patho-) physiological network of
inflammation, hemostasis, and tumor progression and metas-
tasis. Sulfated glycans may interfere with processes where
heparan sulfates or other glycan structures are involved
(Alban, 2008a). Their three-dimensional structure and pat-
terns of charge distribution are responsible for differential
affinities for biomolecules (Stringer et al., 2002). A third
characteristic of sulfated glycans such as heparin and PS3 is
that they do not only highly specifically interact with one
single target structure, but rather act like multivalent
biomodulators and exhibit a wide range of activities
contributing to its overall therapeutic benefit (Alban,
2008b). Similar to combination therapies, the synergism of
various relatively moderate actions finally results in efficacy
with fewer side effects. But their individual activity profiles
are dependent on their individual structure and may
significantly differ. As an example, 30–50% of the molecules
of an unfractionated heparin preparation bind to antithrom-
bin and thus inhibit factor Xa and thrombin, whereas PS3
does not at all exhibit antithrombin-mediated anticoagulant
activity (Yvin et al., 2002). However, PS3 is superior to
heparin in many of its other biological activities (Becker
et al., 2003a). Besides the L- and P-selectin antagonizing
effect, it was shown, to inhibit the chemotaxis of monocytes,
the complement activation, enzymes such as elastase,
hyaluronidase, and heparanase, the release of cytokines, or
to mobilize tissue factor pathway inhibitor.
Compared to heparin doses used to observe a significant
reduction in the inflammatory response in various mouse
models of inflammation (Ludwig et al., 2007b) and also
compared to the anti-inflammatory effect of PS3 in the croton
oil-induced mouse ear edema model (Yvin et al., 2002), the
dose of PS3 (25mg kg1 bodyweight) used here to achieve a
significant immunosuppressive (Figure 5) and anti-inflamma-
tory activity (Figure 6) in mice is higher. However, as we did
not examine the dose–response relationship in this model,
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activity of PS3 at lower doses cannot be excluded. Further,
PS3 used at 25mg kg1 bodyweight has only marginal effects
on coagulation, and was about 10 times more effective than
heparin in experiments directly comparing the effect of PS3
and heparin in models of metastasis (Ludwig and Alban,
unpublished), a process also depending on P- and L-selectin
expression (Borsig et al., 2002).
Supporting the mechanistic linkage between hemostasis
and inflammation, recent clinical research has clearly
documented an increased incidence of cardiovascular
disease in patients suffering from chronic inflammatory
diseases (Maradit-Kremers et al., 2005; Gelfand et al.,
2006; Ludwig et al., 2007a). As numerous immunological
factors identified as relevant in the pathogenesis of athero-
sclerosis are also known to have key functions in other
chronic systemic inflammatory diseases such as rheumatoid
arthritis or psoriasis, a higher than expected rate of
cardiovascular disease could be explained based on shared
pathogenic pathways (Arad et al., 2005; Hansson, 2005;
Boehncke et al., 2007; Ludwig et al., 2007b). P-selectin is a
likely candidate molecule to mediate the close interaction of
chronic inflammation and cardiovascular disease. This notion
is best supported by the defects in leukocyte extravasation
and coagulation in P-selectin-deficient mice (Mayadas et al.,
1993; Subramaniam et al., 1996). Extending these findings,
we have recently provided experimental evidence that
P-selectin-dependent functions of platelets are important in
myocardial infarction and that targeting these functions by
using the small-molecule P-selectin inhibitor efomycine M
(Scho¨n et al., 2002) has a significant therapeutic potential in
relevant animal models (Oostingh et al., 2007b). In addition
to P-selectin inhibition, PS3 possesses a similar in vivo
antithrombotic activity as unfractionated heparin, whereas its
anticoagulant properties are reduced to 20% of unfractio-
nated heparin (Alban et al., 1995).
Overall, PS3 or related substances might target both
inflammation and cardiovascular comorbidity in patients
suffering from chronic inflammatory diseases. However, this
appealing hypothesis remains to be tested.
MATERIALS AND METHODS
Mice
Male C57Bl/6 mice, aged 4–8 weeks, were purchased from Charles
River, Bar Harbor, Maine and kept under specific pathogen-free
conditions with water and food ad libitum. P-selectin-deficient mice
on the C57Bl/6 background were obtained from Jackson Labora-
tories (www.jax.org). L-selectin-deficient mice on the same genetic
background (Borsig et al., 2002) were kindly provided by R Hynes
(Howard Hughes Medical Institute, Massachusetts Institute of
Technology, Cambridge, MA). All animal experiments were
approved by the governmental administration of Hessen (Darmstadt,
Germany).
Cells and culture conditions
Human PBMCs were prepared by Ficoll–Hypaque density gradient
sedimentation (Pharmacia, Uppsala, Sweden) from buffy coats.
U937 cells, a human monocytic cell line expressing the P-selectin
ligand PSGL-1, were cultured at 37 1C and 5% CO2 in RPMI 1640
medium containing 10% fetal calf serum and 1% penicillin–strepto-
mycin solution (all supplements from Sigma, Deisenhofen, Ger-
many). PSGL-1 expression was confirmed by flow cytometry (data
not shown). Cells were used for the rolling experiments within
4 hours after separation, centrifugation, and resuspension in serum-
free medium. E-CHO were grown in MEM-a (Invitrogen, Karlsruhe,
Germany) containing 10% fetal calf serum, 2mM L-glutamine, and
1% penicillin–streptomycin solution. The cells were cultured for 3–4
days to near confluency. After splitting using 0.25% trypsin–EDTA
solution (Sigma), centrifugation, and resuspension in serum-free
medium, the cell suspension was transferred to slowly rotating
plastic tubes. The cells remained in suspension for up to 4 hours. The
rolling experiments were performed within this time period.
Synthesis and characterization of PS3
The synthesis and chemical characterization of PS3 has been
described in detail previously (Yvin et al., 2002; Me´nard et al.,
2004). The starting polymer Phycarine was obtained from Goemar
Laboratoires (Saint-Malo, France). PS3 was produced under Good
Manufacturing Practice conditions. Chemical characterization and
purity tests were performed by means of elemental analysis,
conductivity-detected ion chromatography of the sulfate ions
released by trifluoroacetic acid hydrolysis, conductimetric NaOH
titration of PS3 transformed into the acid form by ion exchange, size
exclusion chromatography, a modified ‘‘methylation analysis’’ (that
is, gas-chromatography-mass spectrometry after derivatization)
(Alban and Franz, 1994), high-pressure anion exchange chromato-
graphy with pulsed amperometric detection analysis, C13NMR, and
UV spectroscopy.
Flow chamber experiments on endothelial cells
Interactions of PBMC with endothelial cells under conditions of
shear flow mimic the situation in blood vessels. This system was
used to determine the effect of selectin inhibition by PS3 or a
cocktail of E-, P-, and L-selectin-directed antibodies on the
interaction between PBMCs and endothelial cells. Human endothe-
lial cells were gently detached from the tissue culture flask by
trypsin/EDTA (PAA Laboratories, Pasching, Germany), followed by
immediate addition of serum-containing medium to inhibit the
action of trypsin. Rectangular plastic tissue culture-treated Therma-
nox coverslips (22 60mm Plano, Wetzlar, Germany) were coated
with 2 104 endothelial cells and left at 37 1C/5% CO2 overnight to
allow the cells to attach, form a normal monolayer, and reexpress
trypsin-sensitive surface antigens. Four hours before the start of the
experiment, recombinant human (rh-) TNF-a was added to the
endothelial cell-coated coverslips at a final concentration of
25 ngml1. TNF-a is known to induce surface expression of
E-selectin and other membrane glycoproteins involved in inter-
actions with flowing lymphocytes. Isolated human PBMCs were
washed and resuspended at 106 cells per milliliter in Hank’s
balanced salt solution containing 2mM CaCl2. An aliquot of 100ml
PS3 at concentrations of 10mgml1 to 10 mgml1 dissolved in 0.9%
NaCl, or of a mix of E-, P-, and L-selectin-specific antibodies (all at a
final concentration of 10 mg per sample) was added to 900ml PBMC
suspension and incubated for at least 20minutes. Transparent flow
chambers with a slit depth of 50 mm and a slit width of 5mm,
equipped with the endothelial cell-coated coverslips, were briefly
rinsed with Hank’s balanced salt solutionþ 2mM CaCl2, and
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connected to a syringe containing the preincubated cell suspension.
Perfusion was performed at 37 1C using a pulse-free pump
under low shear stress conditions (flow rate of 1.12ml per hour,
equivalent to a wall shear rate of 150 per second). Microscopic
phase-contrast images were recorded in real time. At least six
different microscopic fields were recorded for each condition.
The number of adhering cells in all six fields was counted for
analysis. Data presented are from three independently performed
experiments.
Flow chamber experiments on immobilized P-selectin
Microscope glass slides (diameter of 18mm, thickness of 0.2mm)
were used as transparent supports. To achieve a highly homo-
geneous surface, the slides were first treated with a concentrated
H2SO4/H2O2 mixture (7/3 v/v; Fluka, Neu-Ulm, Germany) for
30minutes at 80 1C under ultrasonic conditions and rinsed with
ultrapure water for 30minutes at room temperature. A cleaning
procedure with NH3/H2O2/H2O (1/1/5 v/v/v; Fluka) was performed,
followed by a final rinse with ultrapure water and drying of the
slides. For covalent immobilization of selectins, cyanuric chloride
(Sigma) was used as cross-linker: it was dissolved in chloroform
(Riedel-de Hae¨n, Seelze, Germany) and added to the glass under
ultrasonication. After drying, slides were incubated with a mixture of
3.75mgml1 P-sel-Fc-fusion protein (R&D Systems, Wiesbaden,
Germany) and 0.5% (m/V) BSA (Sigma) in borate buffer (pH 8.8) for
2 hours at room temperature. Immediately before the flow chamber
experiments, slides were thoroughly rinsed with ultrapure water and
incorporated into the flow chamber. Binding of selectin-fusion
protein was confirmed by immunofluorescence (not shown).
The flow apparatus was mounted onto an inverted fluorescence
microscope Axiovert 200 (Carl Zeiss, Germany) as described
previously (Fritzsche et al., 2006). In brief, phosphate-buffered
saline (pH 7.4) containing 1mM CaCl2 and MgCl2 was used as flow
medium at a shear rate of 200 per second, driven by either
hydrostatic pressure or a pump system, respectively. For the flow
experiments using the pump system, 2 106 U937 cells were
injected, and a video sequence was captured after 5minutes of cell
rolling. Then, PS3 (100 mgml1) was added to the streaming
medium, and after 5minutes a second video sequence was recorded.
To quantify a reduction in cell adhesion, the cell number after PS3
injection was compared to that observed in the control experiment.
The video sequences were recorded capturing 25 frames per second
with a CCD camera (CSC 795) using a long-distance objective of
 20. The images were morphometrically analyzed by the
Imagoquant software (Imagoquant Multitrack-AVI-2; Mediquant,
Halle, Germany) resulting in detailed and automated analysis of
the experimental data. All cells (about 100) per image were included
in the calculations.
Flow chamber experiments on immobilized sLexLac1
For experiments using E-CHO cells, cleaned glass slides (described
above) were incubated with monochloro-dimethyl-octadecyl-silane
(Fluka) at 70 1C for 10minutes, which binds covalently to the glass
slides resulting in a hydrophobic monolayer. The binding reaction
was stopped by rinsing with chloroform, washing with water and
drying under air stream conditions. In the next step, lipid monolayers
of 1,2-distearoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids
Inc., Alabaster, AL) as matrix lipid containing 0.01mol% of the
ligand sLexLac1 were preformed on the air–water interphase of the
Langmuir trough. The glycolipid ligand sLexLac1 was synthesized as
previously published (Gege et al., 2000). After condensing the lipid
layer at a lateral pressure of 38mNm1, the glass slides were
vertically driven through the layer resulting in a complete bilayer.
The transfer ratios were between 0.95 and 1.0. The freshly prepared
bilayers were immediately used for the rolling experiments with
E-CHO cells by incorporating the slides into the flow chamber under
exclusion of air contact to warrant the integrity of the bilayers.
Experiments under flow and data analysis were performed as
described above.
Flow chamber experiments on immobilized sLex
The effect of PS3 or an L-selectin-specific antibody on the adherence
and rolling of PBMCs to multimeric sLex was tested under conditions
of shear stress. Rectangular coverslips (24 60mm) were coated
with 2.5 or 5.0 mg biotinylated polyacrylamide labeled with 20%
(molar ratio) sLex and 5% (molar ratio) sulfated tyrosine (sLex/TS-
PAA, 30–40 kDa; Lectinity Holdings Inc., Moscow, Russia). This
ligand has been previously used to analyze L-selectin-mediated
interactions and was shown to have several characteristics in
common with natural L-selectin ligands (Galustian et al., 2002).
The coverslips were air-dried and blocked for at least 1 hour with
0.5% BSA in phosphate-buffered saline. An aliquot of 100ml PS3 at
concentrations of 100 mgml1 dissolved in 0.9% NaCl, or of
L-selectin-specific antibody (at a final concentration of 10mg per
sample) was added to 900 ml peripheral blood lymphocyte suspen-
sion and incubated for at least 20minutes. Transparent flow
chambers with a slit depth of 50 mm and a slit width of 5mm,
equipped with coated or uncoated coverslips, were briefly rinsed
with Hank’s balanced salt solutionþ 2mM CaCl2, and connected to
a syringe containing the preincubated cell suspension. Perfusion was
performed at 37 1C using a pulse-free pump under low shear stress
conditions (flow rate of 1.12ml per hour, equivalent to a wall shear
rate of 150 per second). Microscopic phase-contrast images were
recorded in real time. At least six different microscopic fields were
recorded for each condition. Image analysis was performed offline
using MetaView Imaging software (Universal Imaging Corporation,
Downingtown, PA).
Intravital microscopy of skin microvasculature
Rolling of leukocytes in the skin microvasculature depends on an
interaction of P- and E-selectins with their appropriate leukocyte
ligands (Weninger et al., 2000). To evaluate the influence of P-
selectin inhibition by PS3 in vivo, intravital microscopy of the skin
microvasculature in mice was performed (Ludwig et al., 2004;
Rubant et al., 2008) using human PBMC, whose selectins and
ligands efficiently interact across this species barrier (Robert et al.,
1999). To increase expression of selectin ligand expression
(Zollner et al., 2002), cells were cultured in the presence of the
superantigen TSST-1 for 5 days. Thereafter, cells were labeled with
20,70-bis-(2-carboxyethyl)-5-(and -6)-carboxyfluorescein and injected
retrograde into the aortic arch of anesthetized mice. Labeled cells in
cutaneous microvessels of the left ear were visualized by fluores-
cence epi-illumination. Rolling fractions were determined as
percentages in relation to the total flux. In total, nine vessels from
three C57Bl/6 and seven vessels of two P-selectin-deficient mice
were investigated.
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Adoptive transfer of immunity
For adoptive transfer experiments mice were sensitized by painting
75 ml of DNFB (Sigma) solution (0.5% in acetone/olive oil, 4:1) on
the back of the mice on day 0. Mice were either left untreated,
or received treatments as indicated in the figure legends
immediately after application of DNFB. On day 5, spleens and
regional lymph nodes were removed from DNFB-sensitized mice,
and single cell suspensions were prepared by homogenizing lymph
nodes and spleens from donor mice through a nylon mesh (70 mm
pore width; BD Biosciences, Heidelberg, Germany). Recipient
mice were injected i.v. with 4 107 cells in 200ml total volume,
followed by immediate application of 20 ml DNFB at 0.3% to the
right ears of the mice. At 24 hours after challenge, CHS responses
were determined using a spring-loaded micrometer (Mitutoyo,
Neuss, Germany) in a blinded fashion. Ear swelling responses
of DNFB-challenged ears were compared to the response of
the vehicle-treated ear in and were expressed as cm 103.
Data presented are based on results obtained from 5 to 10 mice
per group.
Cutaneous contact hypersensitivity reaction
Mice were sensitized as described above. On day 5, 20 ml of 0.3%
DNFB or vehicle was applied on the left and right ear, respectively.
At 24 hours after challenge, CHS responses were determined using a
spring-loaded micrometer (Mitutoyo) in a blinded fashion. Ear
swelling responses of DNFB-challenged ears were compared to the
response of the vehicle-treated ear in sensitized animals and were
expressed as cm 103. Mice were either i.v. treated with PS3 at
25mg kg1 bodyweight, or solvent (0.9% NaCl) immediately before
challenge with the allergen.
Statistical analysis
Data are presented as mean±standard error if not indicated
otherwise. Statistical analysis was performed using SigmaStat 3.5
(Systat Software Inc., www.systat.com). Applied tests are indicated at
the figure legends. P-values o0.05 were considered statistically
significant. All statistical tests were two sided.
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